REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Fixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are expected to soon become standard practice in first-line patients with chronic lymfocytic leukemia (CLL). The advantage of a fixed duration venetoclax combination as part of first-line treatment is the potential to retreat with venetoclax in patients who develop relapsed disease after a treatment free period. However, efficacy of venetoclax retreatment following a fixed duration venetoclax combination is still hypothetical as clinical data are lacking. Thus, there is an urgent need for data proving efficacy of venetoclax combinations following venetoclax treatment cessation. Testing of a novel venetoclax-containing regimen for relapsed CLL without the repeat of anti-CD20 monoclonal antibody (mAb) is a rational approach.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznana białaczka limfocytowa lub podobna choroba, która powróciła po wcześniejszym leczeniu venetoclaxem z innymi lekami
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG 0-3)
- •Prawidłowa liczba komórek krwi: hemoglobina powyżej 8 g/dL, granulocyty powyżej 750/μL, płytki powyżej 30 000/μL
- •Prawidłowe funkcje nerek (eGFR lub klirens kreatyniny co najmniej 30 ml/min)
- •Prawidłowe funkcje wątroby (enzymy wątrobowe do 3-krotności normy, bilirubina do 1,5-krotności normy)
- •Prawidłowe parametry krzepnięcia (PT/INR i aPTT poniżej 1,5-krotności normy)
- •Ujemne testy na wirusy zapalenia wątroby B i C (lub negatywny PCR w ciągu 6 tygodni)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
BE-Bruxelles-STLUC
Brussels, Belgium
BE-Leuven-UZLEUVEN
Leuven, Belgium
DK-Aarhus N-AUH
Aarhus, Denmark
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands
NL-Amsterdam-AMC
Amsterdam, Netherlands
NL-Arnhem-RIJNSTATE
Arnhem, Netherlands
NL-Breda-AMPHIA
Breda, Netherlands
NL-Delft-RDGG
Delft, Netherlands
NL-Dordrecht-ASZ
Dordrecht, Netherlands
NL-Ede-ZGV
Ede, Netherlands
NL-Eindhoven-MAXIMAMC
Eindhoven, Netherlands
NL-Groningen-UMCG
Groningen, Netherlands
NL-Leeuwarden-MCL
Leeuwarden, Netherlands
NL-Maastricht-MUMC
Maastricht, Netherlands
NL-Nieuwegein-ANTONIUS
Nieuwegein, Netherlands
NL-Rotterdam-IKAZIA
Rotterdam, Netherlands
NL-Rotterdam-MAASSTADZIEKENHUIS
Rotterdam, Netherlands
NL-Utrecht-UMCUTRECHT
Utrecht, Netherlands
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.